Insight

Oct 31, 2024, 06:01

Nico Gagelmann: Bs Abs as bridging to BCMA CAR-T cell therapy for R/R multiple myeloma

Nico Gagelmann, Co- Chair of the The EBMT Trainee Committee, shared on X:

“Finally out!

Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma.”

Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma

Authors: David Fandrei, Sabine Seiffert, Michael Rade, Susanne Rieprecht, Nico Gagelmann, Patrick Born, Thomas Wiemers, Heike Weidner, Markus Kreuz, Tamara Schassberger, Jannik Kossmann, Marlene Mangold, Daniel Furst, Luise Fischer, Ronny Baber, Simone Heyn, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Klaus H. Metzeler, Marco Herlling, Madlen Jentzsch, Georg-Nikolaus Franke, Ulrike Kohl, Maik Friedrich, Andreas Boldt, Kristin Reiche, Uwe Platzbecker, Vladan Vucinic, Maximilian Merz.

Nico Gagelmann

Andreas Boldt Bispecific antibodies cancer Daniel Furst David Fandrei Enrica Bach Georg-Nikolaus Franke Heike Weidner Jannik Kossmann Klaus H Metzeler Kristin Reiche Luise Fischer Madlen Jentzsch Maik Friedrich Marco Herlling Markus Kreuz Marlene Mangold Maximilian Merz Michael Rade multiple myeloma Nico Gagelmann OncoDaily Oncology Patrick Born Ronny Baber Sabine Seiffert Sandra Hoffmann Simone Heyn Song Yau Wang Susanne Rieprecht Tamara Schassberger Thomas Wiemers Ulrike Köhl Uwe Platzbecker Vladan Vucinic

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage